Treatment of BRAF-Mutated Metastatic Melanoma: Immunotherapy or Target Therapy?
Metastatic melanoma has been associated with a poor prognosis, with overall survival rates at 5 years of 10%. Until 2011, the only treatments available for metastatic melanoma were chemotherapy and immunotherapy with interleukin-2. The more in-depth knowledge about the molecular biology of melanoma...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | ספר |
| יצא לאור: |
Sociedade Portuguesa de Dermatologia e Venereologia,
2021-06-01T00:00:00Z.
|
| נושאים: | |
| גישה מקוונת: | Connect to this object online. |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|